Lower Corticosteroid Injection Rates With Secukinumab vs Interleukin-23 Inhibitors: A Real-World Study of Corticosteroid Use Among Patients With Psoriatic Arthritis (ACR Convergence 2026) - Sep 8, 2026 - Abstract #364; Pres time: Nov 8, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; In Person; "Commonly used agents with real-world evidence include the IL-17Ai secukinumab (SEC) and the IL-23is risankizumab (RIS) and guselkumab (GUS). In this real-world cohort of patients with PsA initiating SEC, RIS, or GUS, SEC was associated with ≈23% lower CS injection rates over 12 months vs IL-23i therapy, consistent with lower rescue treatment use. Figure 1. Study design Figure 2."
Clinical • Real-world • Real-world evidence • Immunology • Inflammatory Arthritis • Psoriasis • Psoriatic Arthritis • Rheumatology • Seronegative Spondyloarthropathies • IL23A
|
|
Adanna Obioha1; Riley Taiji1; Francis Vekeman1; Linda Grinnell-Merrick2; Rachel Tate2; Tim Nguyen3
|